Online citations, reference lists, and bibliographies.
← Back to Search

Intranasal Vaccines: Forthcoming Challenges.

Partidos
Published 2000 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The mucosal epithelium of the upper respiratory tract constitutes an effective physical barrier to many pathogens. Its mucosal-associated lymphoid tissue is of particular importance for the protection and integrity of mucosal surfaces and the body's interior. Understanding the factors that influence the induction and regulation of mucosal immune responses will facilitate the design of vaccines capable of eliciting the appropriate type of protective immune response.
This paper references
10.1073/PNAS.93.7.2879
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.
D. Klinman (1996)
10.1111/j.2042-7158.1993.tb05532.x
Immune Response to Nasal Delivery of Antigenically Intact Tetanus Toxoid Associated with Poly(l‐lactic acid) Microspheres in Rats, Rabbits and Guinea‐pigs
A. Almeida (1993)
10.1016/S0165-2478(97)86163-9
Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
L. Ågren (1997)
10.1016/B978-012410580-5/50012-1
11 – Recombinant Adenoviruses as Vectors for Mucosal Immunity
K. Rosenthal (1996)
10.1016/0167-7799(96)10053-6
Antisense oligonucleotides: towards clinical trials.
S. Agrawal (1996)
10.1038/308457A0
Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses
B. Morein (1984)
10.1046/j.1365-3083.1997.d01-159.x
Nasal Lymphoid Tissue (NALT) as a Mucosal Immune Inductive Site
H. Wu (1997)
10.1099/0022-1317-77-10-2471
Mucosal and systemic immune responses to measles virus haemagglutinin in mice immunized with a recombinant vaccinia virus.
N. Etchart (1996)
10.1084/JEM.180.6.2147
A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit
M. Pizza (1994)
10.1007/978-3-642-59951-4_10
Host responses to respiratory virus infection and immunization.
J. Crowe (1999)
10.1093/INFDIS/168.3.622
Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B.
W. S. Gallichan (1993)
10.1016/B978-012410580-5/50013-3
12 – Poly(lactide-co-glycolide) Microencapsulation of Vaccines for Mucosal Immunization
J. Duncan (1996)
10.1073/PNAS.97.2.811
Cationic microparticles: A potent delivery system for DNA vaccines.
M. Singh (2000)
10.1016/0161-5890(91)90076-V
Biodegradable microspheres as a vaccine delivery system.
J. Eldridge (1991)
10.1046/j.1365-2567.1996.462527.x
Induction of measles virus‐specific cytotoxic T‐cell responses after intranasal immunization with synthetic peptides
C. Partidos (1996)
10.3109/00016489109138388
The Waldeyer ring equivalent in the rat. A model for analysis of oronasopharyngeal immune responses.
P. Koornstra (1991)
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
M. McCluskie (1998)
10.1002/EJI.1830220915
The adjuvant effect of Vibrio cholerae and Escherichia coli heat‐labile enterotoxins is linked to their ADP‐ribosyltransferase activity
N. Lycke (1992)
10.1084/JEM.178.5.1783
Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice
G. Hoyne (1993)
10.1002/EJI.1830250417
Intranasal immunization with liposomes induces strong mucosal immune responses in mice
J. Vadolas (1995)
10.1046/j.1365-2567.1996.d01-790.x
The adjuvant effect of a non‐toxic mutant of heat‐labile enterotoxin of Escherichia coli for the induction of measles virus‐specific CTL responses after intranasal co‐immunization with a synthetic peptide
C. Partidos (1996)
In vivo responses to inhaled proteins. I. Quantitative analysis of antigen uptake, fate, and immunogenicity in a rabbit model system.
J. B. Willoughby (1977)
10.1016/S0264-410X(96)00266-6
Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration.
D. I. Jones (1997)
10.1007/978-3-642-75605-4_6
Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function.
J. Bennink (1990)
A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
M. Yamamoto (1998)
10.1128/JVI.73.5.4120-4126.1999
CpG-Containing Oligonucleotides Are Efficient Adjuvants for Induction of Protective Antiviral Immune Responses with T-Cell Peptide Vaccines
A. Oxenius (1999)
10.1038/15058
Advances in vaccine adjuvants
M. Singh (1999)
10.1016/0167-5699(90)90034-7
Immunological adjuvants: a role for liposomes.
G. Gregoriadis (1990)
10.1002/(SICI)1521-4141(199803)28:03<1069::AID-IMMU1069>3.0.CO;2-P
Fibronectin‐binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route
E. Medina (1998)
Vaccines. New approaches to immunological problems.
R. Ellis (1992)
10.1172/JCI118894
Activation of human B cells by phosphorothioate oligodeoxynucleotides.
H. Liang (1996)
10.1126/SCIENCE.8493576
Protection against vaginal SIV transmission with microencapsulated vaccine.
P. Marx (1993)
10.1016/0264-410X(92)90021-B
The mucosal immune system: from fundamental concepts to vaccine development.
J. Mcghee (1992)
10.1038/NEWBIO238238A0
Haemoglobin polymorphism in the Rhesus macaque.
R. Basch (1972)
10.1038/NM0897-849
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
M. Roman (1997)
10.1111/j.1600-065X.1991.tb00575.x
Detection of Human Cytokine‐Secreting Cells in Distinct Anatomical Compartments
C. Czerkinsky (1991)
10.1084/JEM.184.5.1879
Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization
W. S. Gallichan (1996)
10.1016/B978-012410580-5/50006-6
5 – Use of Escherichia coli Heat-Labile Enterotoxin as an Oral Adjuvant
B. L. Dickinson (1996)
10.1128/IAI.65.10.4288-4298.1997
Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins.
P. Giannasca (1997)
10.1016/0167-5699(92)90158-4
The role of nasopharyngeal lymphoid tissue.
C. Kuper (1992)
10.1016/S0076-6879(85)16005-2
[3] Immunoglobulin A (IgA)
J. Mestecky (1985)
10.1038/273238A0
Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus
K. Yap (1978)
10.1084/JEM.183.4.1561
Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes
J. Tian (1996)
10.1016/0959-437X(93)90126-A
Gene therapy: adenovirus vectors.
K. Kozarsky (1993)
10.1093/INFDIS/167.3.752
Microencapsulated human parainfluenza virus induces a protective immune response.
R. Ray (1993)
10.1016/S0167-5699(98)01307-3
Immunology of the tonsils.
M. Perry (1998)
IL-12 is an effective adjuvant for induction of mucosal immunity.
P. Boyaka (1999)
10.1084/JEM.187.7.1123
Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity
M. Giuliani (1998)
10.1073/PNAS.96.8.4512
Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.
I. Belyakov (1999)
Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
M. Marinaro (1999)
10.1016/0167-5699(91)90133-E
ISCOMS--a novel strategy for mucosal immunization?
A. Mowat (1991)
10.1016/0264-410X(93)90309-L
Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization.
S. Czinn (1993)
10.1016/S0264-410X(99)00128-0
Iscoms with different quillaja saponin components differ in their immunomodulating activities.
M. Johansson (1999)
10.1016/S0065-3527(08)60515-1
Vaccinia: virus, vector, vaccine.
A. Piccini (1988)
10.1016/S0264-410X(98)80122-9
CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus.
Z. Moldoveanu (1998)
10.1128/MMBR.56.4.622-647.1992
Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.
B. Spangler (1992)
10.1128/IAI.64.3.974-979.1996
Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant.
A. Di Tommaso (1996)
10.1016/0161-5890(96)00032-6
Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes.
C. Partidos (1996)
10.1084/JEM.171.4.979
Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function
R. Daynes (1990)
10.1099/0022-1317-73-2-359
Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice.
T. Wild (1992)
Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues.
M. Mcdermott (1979)
10.1016/0264-410X(91)90220-Z
The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane.
S. Gizurarson (1991)
Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
L. Ågren (1999)
10.1016/0378-1119(83)90163-4
Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA.
G. Smith (1983)
10.1016/S0065-2776(08)60240-0
Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response.
J. Mestecky (1987)
10.1002/EJI.1830250203
Human circulating specific antibody‐forming cells after systemic and mucosal immunizations: differential homing commitments and cell surface differentiation markers
M. Quiding-Järbrink (1995)
10.1038/321209A0
CpG-rich islands and the function of DNA methylation
A. Bird (1986)
10.1007/978-1-4615-3410-5_2
Mucosal immunity to vaccines: current concepts for vaccine development and immune response analysis.
J. Mcghee (1992)
10.1038/372552A0
Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi
S. Langermann (1994)
Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector.
G. Fennelly (1999)
10.1128/IAI.65.7.2821-2828.1997
Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.
G. Douce (1997)
Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts.
L. Klavinskis (1999)
10.1146/ANNUREV.IMMUNOL.14.1.275
Antigen sampling across epithelial barriers and induction of mucosal immune responses.
M. Neutra (1996)
10.1016/B978-0-7506-9265-6.50022-1
Adenovirus-based expression vectors and recombinant vaccines.
F. Graham (1992)
IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens.
H. Staats (1999)
10.1128/JVI.61.8.2624-2626.1987
Immunoglobulin A monoclonal antibodies protect against Sendai virus.
M. Mazanec (1987)
10.1128/JVI.65.8.4494-4497.1991
Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells.
J. L. Munoz (1991)
10.1038/374546A0
CpG motifs in bacterial DNA trigger direct B-cell activation
Arthur M. Krieg (1995)
10.1084/JEM.187.1.1
Early Murine Cytomegalovirus (MCMV) Infection Induces Liver Natural Killer (NK) Cell Inflammation and Protection Through Macrophage Inflammatory Protein 1α (MIP-1α)–dependent Pathways
T. P. Salazar-Mather (1998)
10.1016/S0264-410X(96)00074-6
Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres.
Y. Men (1996)
10.1084/JEM.160.3.814
In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific
A. Lukacher (1984)
10.1097/00062752-200101000-00009
Th1 and Th2 cells.
C. Dong (2001)
10.1038/351456A0
New use of BCG for recombinant vaccines
C. Stover (1991)
10.1016/S0167-5699(98)01431-5
Delivery of DNA vaccines by attenuated intracellular bacteria.
G. Dietrich (1999)
10.1016/B978-012410580-5/50005-4
4 – Cholera Toxin as a Mucosal Adjuvant
C. Elson (1996)
Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant.
M. Yamamoto (1999)
10.1146/ANNUREV.IY.07.040189.001045
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.
T. Mosmann (1989)
10.1016/S0165-2478(99)00013-9
Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides.
C. Partidos (1999)



This paper is referenced by
10.1159/000071154
Anatomy of the Nasal Cavity in the Chinchilla
J. Jurcisek (2003)
10.1016/S0168-3659(02)00268-7
Applying peptide antigens onto bare skin: induction of humoral and cellular immune responses and potential for vaccination.
C. Partidos (2002)
10.1016/j.vaccine.2014.03.041
Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization.
Q. Liu (2014)
10.1016/j.vaccine.2013.09.033
Intranasal immunization with a non-adjuvanted adhesive protein descended from Pasteurella pneumotropica and its preventive efficacy against opportunistic infection in mice.
H. Sasaki (2013)
10.1016/j.vetmic.2019.108401
Evaluation of CpG-ODN-adjuvanted polyanhydride-based intranasal influenza nanovaccine in pigs.
S. Dhakal (2019)
Mucoadhesive Nanocarriers for Nasal Delivery of Vaccines
R. Sonawane (2016)
10.1016/J.PROVAC.2009.07.027
Liposome in situ gelling system: Novel carrier based vaccine adjuvant for intranasal delivery of recombinant protein vaccine
Shailja Tiwari (2009)
10.1016/j.vetimm.2009.08.011
NALT (nasal cavity-associated lymphoid tissue) in the rabbit.
C. Casteleyn (2010)
10.1128/CVI.05117-11
Intranasal Administration of an Inactivated Yersinia pestis Vaccine with Interleukin-12 Generates Protective Immunity against Pneumonic Plague #
D. Kumar (2011)
10.1089/0894268041457183
PEG-PLA nanoparticles as carriers for nasal vaccine delivery.
A. Vila (2004)
10.1016/j.ijmm.2016.08.004
Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model.
Q. Liu (2016)
10.4049/jimmunol.0903357
NK Cells Influence Both Innate and Adaptive Immune Responses after Mucosal Immunization with Antigen and Mucosal Adjuvant
L. Hall (2010)
Noninvasive immunization strategies to target dendritic cells and protect against experimental otitis media due to nontypeable Haemophilus influenzae
L. Novotny (2011)
10.3858/emm.2009.41.11.087
Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with β2-adrenergic agonist
S. Kim (2009)
Development of alternative micro and nanoparticulate polymeric systems for mucosal delivery of Streptococcus equi antigens
H. Florindo (2008)
10.1016/j.ijpharm.2007.11.027
Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
Kapil Khatri (2008)
10.1016/J.EJPB.2003.09.006
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)
10.1211/002235702320402035
Intranasal administration of plasmid DNA‐coated nanoparticles results in enhanced immune responses
Z. Cui (2002)
10.1046/j.1365-2567.2001.01183.x
Immunization onto bare skin with heat‐labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge
A. Beignon (2001)
10.1208/pt0804081
Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination
Robert J. Garmise (2008)
10.1371/journal.pone.0053314
Preparation and Efficacy of a Live Newcastle Disease Virus Vaccine Encapsulated in Chitosan Nanoparticles
K. Zhao (2012)
Generates Protective Immunity against Pneumonic Plague
Devender Kumar (2011)
10.1016/J.VETMIC.2005.11.062
The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice.
Omar Farnós (2006)
10.22092/ARI.2008.103739
PREPARATION AND IN-VITRO EVALUATION OF SODIUM ALGINATE MICROSPHERES CONTAINING DIPHTHERIA TOXOID AS NEW VACCINE DELIVERY
A. Mokaram (2008)
10.1208/s12249-020-01689-x
Cationic Polylactic Acid-Based Nanoparticles Improve BSA-FITC Transport Across M Cells and Engulfment by Porcine Alveolar Macrophages
Puwich Chaikhumwang (2020)
10.4155/TDE.10.19
Advances in effective vaccine development against hepatitis B: focus on mucosal vaccine delivery strategies.
Rishi Paliwal (2010)
10.1080/14760584.2017.1395702
Development of a nanogel-based nasal vaccine as a novel antigen delivery system
Rika Nakahashi-Ouchida (2017)
10.1016/J.POWTEC.2016.01.042
Carrier-based dry powder formulation for nasal delivery of vaccines utilizing BSA as model drug
Sabrina Trows (2016)
IMMUNITY IN THE RESPIRATORY TRACT : THE ROLE OF IgA IN PROTECTION AGAINST INTRACELLULAR
A. Rodríguez (2005)
10.1016/j.addr.2021.01.003
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
Deborah Pushparajah (2021)
This information is current as Adjuvant Immunization with Antigen and Mucosal Immune Responses after Mucosal NK Cells Influence Both Innate and Adaptive
Lindsay J Hall (2010)
10.22092/ARI.2006.103722
Preparation and evaluation of chitosan nanoparticles containing Diphtheria toxoid as new carriers for nasal vaccine delivery in mice
A. Mokarram (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar